| abstract |
(57) [Summary]nDisclosed are methods and compositions for preventing undesirable visual abnormalities commonly experienced by patients undergoing refractive surgery, including photophobia, glare, double vision, and halos, but not those abnormalities. . In particular, the present disclosure provides for topical application of the ophthalmic solution to the eye, wherein the ophthalmic solution contains one or more alpha-adrenergic blockers, preferably thymoxamine, in a therapeutically effective amount. The present disclosure further provides an ophthalmic solution containing one or more alpha-adrenergic blockers in a physiologically acceptable carrier, wherein the ophthalmic solution is administered at an effective dose such that its concentration and release rate are therapeutically effective. It can be administered to a subject. One or more visual abnormalities experienced by patients undergoing refractive surgery that contain one or more alpha-adrenergic blockers in combination with one or more anti-irritants and / or one or more anti-inflammatory agents Also disclosed is an ophthalmic solution for preventing odor. |